| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Photochemotherapy | 25 | 2020 | 101 | 2.530 |
Why?
|
| Ultraviolet Therapy | 8 | 2018 | 17 | 1.280 |
Why?
|
| Psoriasis | 16 | 2018 | 254 | 1.200 |
Why?
|
| Aminolevulinic Acid | 14 | 2012 | 23 | 1.060 |
Why?
|
| Photosensitizing Agents | 14 | 2020 | 52 | 0.970 |
Why?
|
| Dermatologic Agents | 3 | 2018 | 77 | 0.920 |
Why?
|
| Protoporphyrins | 8 | 2006 | 19 | 0.690 |
Why?
|
| Methoxsalen | 12 | 2001 | 15 | 0.600 |
Why?
|
| Ultraviolet Rays | 15 | 2015 | 198 | 0.530 |
Why?
|
| PUVA Therapy | 15 | 1999 | 24 | 0.510 |
Why?
|
| Biological Products | 1 | 2018 | 179 | 0.480 |
Why?
|
| Photosensitivity Disorders | 8 | 1992 | 15 | 0.420 |
Why?
|
| Skin Diseases | 3 | 2010 | 176 | 0.410 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 90 | 0.400 |
Why?
|
| Skin Neoplasms | 11 | 2017 | 625 | 0.370 |
Why?
|
| Keratinocytes | 4 | 2015 | 146 | 0.360 |
Why?
|
| Immunoglobulin G | 2 | 2013 | 481 | 0.350 |
Why?
|
| Porphyrins | 8 | 2012 | 37 | 0.340 |
Why?
|
| Laser Therapy | 3 | 2017 | 151 | 0.290 |
Why?
|
| Carcinoma, Basal Cell | 5 | 2017 | 63 | 0.280 |
Why?
|
| Prostatic Neoplasms | 6 | 2006 | 1798 | 0.250 |
Why?
|
| Cell Differentiation | 4 | 2020 | 1667 | 0.250 |
Why?
|
| Lasers, Gas | 2 | 2017 | 4 | 0.240 |
Why?
|
| Sebaceous Glands | 1 | 2006 | 28 | 0.240 |
Why?
|
| Cryotherapy | 2 | 2017 | 30 | 0.240 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2001 | 100 | 0.240 |
Why?
|
| Deferoxamine | 4 | 1995 | 18 | 0.220 |
Why?
|
| Vitiligo | 4 | 1988 | 19 | 0.210 |
Why?
|
| Vitamin D | 3 | 2020 | 273 | 0.200 |
Why?
|
| Humans | 63 | 2018 | 96105 | 0.170 |
Why?
|
| Receptors, Immunologic | 2 | 2000 | 145 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 10 | 2002 | 1049 | 0.170 |
Why?
|
| Skin | 11 | 1999 | 605 | 0.170 |
Why?
|
| Khellin | 4 | 1988 | 4 | 0.160 |
Why?
|
| Erythema | 5 | 1999 | 33 | 0.160 |
Why?
|
| Hyperthermia, Induced | 1 | 2000 | 75 | 0.150 |
Why?
|
| Neoplasms, Experimental | 1 | 2000 | 270 | 0.150 |
Why?
|
| Keratosis, Actinic | 2 | 2015 | 13 | 0.140 |
Why?
|
| Europe | 1 | 2018 | 349 | 0.130 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 7229 | 0.130 |
Why?
|
| Male | 28 | 2018 | 45863 | 0.130 |
Why?
|
| Dermatitis, Photoallergic | 2 | 1995 | 2 | 0.130 |
Why?
|
| Lymphomatoid Granulomatosis | 2 | 1987 | 5 | 0.130 |
Why?
|
| Combined Modality Therapy | 6 | 2013 | 1773 | 0.130 |
Why?
|
| Physicians, Primary Care | 1 | 2018 | 110 | 0.130 |
Why?
|
| Aged | 14 | 2018 | 20968 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 449 | 0.120 |
Why?
|
| Adolescent | 6 | 2018 | 9895 | 0.120 |
Why?
|
| Disease Management | 1 | 2018 | 360 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 1267 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2018 | 391 | 0.110 |
Why?
|
| Scalp Dermatoses | 1 | 2014 | 10 | 0.110 |
Why?
|
| Facial Dermatoses | 1 | 2014 | 15 | 0.110 |
Why?
|
| Middle Aged | 15 | 2018 | 28368 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 1994 | 31 | 0.100 |
Why?
|
| Baths | 4 | 1994 | 10 | 0.100 |
Why?
|
| Young Adult | 2 | 2018 | 7025 | 0.100 |
Why?
|
| Etanercept | 1 | 2013 | 33 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2001 | 1730 | 0.100 |
Why?
|
| Female | 21 | 2018 | 50028 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2015 | 1105 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 2061 | 0.100 |
Why?
|
| Netherton Syndrome | 1 | 2012 | 2 | 0.090 |
Why?
|
| Adult | 15 | 2018 | 28721 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1979 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 873 | 0.090 |
Why?
|
| Methotrexate | 4 | 2012 | 249 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 162 | 0.090 |
Why?
|
| Cutis Laxa | 1 | 1992 | 4 | 0.090 |
Why?
|
| Elastic Tissue | 1 | 1992 | 18 | 0.090 |
Why?
|
| Melanoma | 3 | 2013 | 497 | 0.090 |
Why?
|
| Skin Aging | 1 | 1992 | 32 | 0.090 |
Why?
|
| Indoles | 1 | 2013 | 317 | 0.090 |
Why?
|
| Superoxide Dismutase | 2 | 1999 | 156 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2018 | 3110 | 0.090 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2003 | 84 | 0.090 |
Why?
|
| Phagocytosis | 1 | 1992 | 116 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2017 | 4671 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 247 | 0.090 |
Why?
|
| Recurrence | 2 | 2013 | 1218 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2013 | 337 | 0.090 |
Why?
|
| Riboflavin | 1 | 1990 | 7 | 0.080 |
Why?
|
| Loose Anagen Hair Syndrome | 1 | 2010 | 5 | 0.080 |
Why?
|
| Hair | 1 | 2010 | 56 | 0.080 |
Why?
|
| Rats | 8 | 2003 | 4155 | 0.080 |
Why?
|
| Ovarian Neoplasms | 3 | 2001 | 801 | 0.080 |
Why?
|
| Leiomyoma | 1 | 2013 | 211 | 0.080 |
Why?
|
| Animals | 19 | 2006 | 28891 | 0.080 |
Why?
|
| DNA | 4 | 1993 | 1333 | 0.080 |
Why?
|
| Light | 4 | 2006 | 297 | 0.080 |
Why?
|
| Sulfadoxine | 1 | 1989 | 2 | 0.070 |
Why?
|
| Sulfanilamides | 1 | 1989 | 5 | 0.070 |
Why?
|
| Pyrimethamine | 1 | 1989 | 21 | 0.070 |
Why?
|
| Chloroquine | 1 | 1989 | 12 | 0.070 |
Why?
|
| Cell Line | 2 | 2006 | 2537 | 0.070 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 1989 | 23 | 0.070 |
Why?
|
| Lipid Peroxidation | 1 | 2009 | 47 | 0.070 |
Why?
|
| Malaria | 1 | 1989 | 26 | 0.070 |
Why?
|
| Antimalarials | 1 | 1989 | 21 | 0.070 |
Why?
|
| Mice | 9 | 2006 | 12537 | 0.070 |
Why?
|
| Complement Activation | 1 | 2009 | 84 | 0.070 |
Why?
|
| Niacinamide | 1 | 1988 | 102 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2009 | 303 | 0.070 |
Why?
|
| Microscopy, Confocal | 2 | 2006 | 286 | 0.070 |
Why?
|
| Metribolone | 2 | 2006 | 5 | 0.060 |
Why?
|
| Macrophages | 4 | 2001 | 623 | 0.060 |
Why?
|
| Eyelid Diseases | 1 | 1986 | 6 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2014 | 9175 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2006 | 445 | 0.060 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2003 | 11 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 7 | 2001 | 192 | 0.060 |
Why?
|
| Mitochondria | 3 | 2006 | 622 | 0.060 |
Why?
|
| Mice, Nude | 3 | 2001 | 830 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2001 | 2090 | 0.060 |
Why?
|
| Sunlight | 3 | 2015 | 28 | 0.060 |
Why?
|
| Apoptosis | 2 | 2009 | 1756 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2001 | 1192 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 871 | 0.050 |
Why?
|
| Administration, Oral | 5 | 2002 | 688 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 262 | 0.050 |
Why?
|
| Euglena gracilis | 2 | 1994 | 8 | 0.050 |
Why?
|
| Chlorophyllides | 2 | 2001 | 5 | 0.050 |
Why?
|
| Hydro-Lyases | 2 | 1994 | 7 | 0.050 |
Why?
|
| Alcohol Oxidoreductases | 2 | 1994 | 17 | 0.050 |
Why?
|
| Lyases | 2 | 1994 | 11 | 0.050 |
Why?
|
| Alkyl and Aryl Transferases | 2 | 1994 | 17 | 0.050 |
Why?
|
| Multienzyme Complexes | 2 | 1994 | 63 | 0.050 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1994 | 81 | 0.050 |
Why?
|
| Piperazines | 2 | 2003 | 296 | 0.050 |
Why?
|
| Testosterone Congeners | 1 | 2002 | 2 | 0.050 |
Why?
|
| Pyrimidines | 2 | 2003 | 386 | 0.050 |
Why?
|
| Cell Division | 4 | 2002 | 705 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 656 | 0.050 |
Why?
|
| Tretinoin | 1 | 2002 | 131 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2001 | 70 | 0.040 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2002 | 35 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2001 | 2939 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2001 | 297 | 0.040 |
Why?
|
| Deuteroporphyrins | 1 | 2001 | 1 | 0.040 |
Why?
|
| Organotin Compounds | 1 | 2001 | 1 | 0.040 |
Why?
|
| Mutagenesis, Insertional | 1 | 2001 | 116 | 0.040 |
Why?
|
| Cell Survival | 3 | 2006 | 1030 | 0.040 |
Why?
|
| Biopsy | 3 | 1992 | 1220 | 0.040 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2000 | 5 | 0.040 |
Why?
|
| Receptors, Scavenger | 1 | 2000 | 5 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2002 | 728 | 0.040 |
Why?
|
| DNA Primers | 1 | 2001 | 548 | 0.040 |
Why?
|
| Serum Albumin, Bovine | 1 | 2000 | 47 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2001 | 180 | 0.040 |
Why?
|
| Phenylalanine | 1 | 2000 | 36 | 0.040 |
Why?
|
| Hematoporphyrin Derivative | 2 | 1996 | 3 | 0.040 |
Why?
|
| Thiophenes | 1 | 2000 | 45 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2000 | 88 | 0.040 |
Why?
|
| Antibodies, Antinuclear | 2 | 1992 | 95 | 0.040 |
Why?
|
| DNA Replication | 2 | 1993 | 177 | 0.040 |
Why?
|
| Follow-Up Studies | 6 | 1996 | 3927 | 0.040 |
Why?
|
| Integrin beta1 | 1 | 1999 | 34 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2001 | 376 | 0.040 |
Why?
|
| Impetigo | 1 | 1999 | 1 | 0.040 |
Why?
|
| Bowen's Disease | 2 | 1996 | 9 | 0.040 |
Why?
|
| Dermatitis Herpetiformis | 1 | 1999 | 9 | 0.040 |
Why?
|
| Neoplasms | 2 | 2012 | 3248 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1999 | 130 | 0.040 |
Why?
|
| Time Factors | 5 | 2002 | 5580 | 0.040 |
Why?
|
| Porphobilinogen Synthase | 1 | 1998 | 4 | 0.040 |
Why?
|
| Phototherapy | 1 | 2018 | 36 | 0.040 |
Why?
|
| Heme | 1 | 1998 | 64 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 996 | 0.040 |
Why?
|
| Temperature | 1 | 1999 | 426 | 0.030 |
Why?
|
| Biological Therapy | 1 | 2018 | 47 | 0.030 |
Why?
|
| Transferases | 2 | 1994 | 23 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2009 | 3581 | 0.030 |
Why?
|
| Hordeum | 1 | 1997 | 11 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 1645 | 0.030 |
Why?
|
| Plant Growth Regulators | 1 | 1997 | 12 | 0.030 |
Why?
|
| Cyclopentanes | 1 | 1997 | 28 | 0.030 |
Why?
|
| Torso | 1 | 2017 | 14 | 0.030 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 1997 | 99 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 1999 | 482 | 0.030 |
Why?
|
| Genes, Plant | 2 | 1997 | 102 | 0.030 |
Why?
|
| Skin Pigmentation | 2 | 1988 | 36 | 0.030 |
Why?
|
| Administration, Cutaneous | 2 | 1993 | 61 | 0.030 |
Why?
|
| Photochemistry | 2 | 2001 | 38 | 0.030 |
Why?
|
| Pemphigoid, Bullous | 1 | 1996 | 12 | 0.030 |
Why?
|
| Extremities | 1 | 2017 | 179 | 0.030 |
Why?
|
| Dermatology | 1 | 1996 | 46 | 0.030 |
Why?
|
| Neoplasm Transplantation | 3 | 2002 | 411 | 0.030 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1995 | 16 | 0.030 |
Why?
|
| Sunburn | 1 | 2015 | 8 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1995 | 28 | 0.030 |
Why?
|
| Sunscreening Agents | 1 | 2015 | 10 | 0.030 |
Why?
|
| Pyoderma Gangrenosum | 1 | 1995 | 20 | 0.030 |
Why?
|
| Patch Tests | 1 | 1995 | 4 | 0.030 |
Why?
|
| Survival Rate | 2 | 2002 | 1985 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 1670 | 0.030 |
Why?
|
| Erythrocytes | 3 | 1990 | 254 | 0.030 |
Why?
|
| Child | 4 | 1996 | 7625 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 1986 | 298 | 0.030 |
Why?
|
| Deoxyribodipyrimidine Photo-Lyase | 1 | 1993 | 1 | 0.030 |
Why?
|
| Pyrimidine Dimers | 1 | 1993 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2002 | 1973 | 0.030 |
Why?
|
| Fibroblasts | 2 | 1994 | 777 | 0.030 |
Why?
|
| Dermatitis, Phototoxic | 1 | 1993 | 2 | 0.030 |
Why?
|
| Calcium | 1 | 1998 | 1205 | 0.030 |
Why?
|
| Phosphotransferases | 1 | 1993 | 64 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1993 | 41 | 0.020 |
Why?
|
| Oxygen Consumption | 2 | 2006 | 253 | 0.020 |
Why?
|
| Thymidine | 1 | 1993 | 59 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1993 | 119 | 0.020 |
Why?
|
| Darkness | 1 | 1993 | 49 | 0.020 |
Why?
|
| Glycine | 1 | 1993 | 96 | 0.020 |
Why?
|
| Gene Amplification | 1 | 1993 | 143 | 0.020 |
Why?
|
| Skin Tests | 2 | 1993 | 47 | 0.020 |
Why?
|
| Methylprednisolone | 2 | 1995 | 68 | 0.020 |
Why?
|
| Oxygen | 2 | 2012 | 781 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1993 | 237 | 0.020 |
Why?
|
| Plant Proteins | 1 | 1993 | 143 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 336 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1429 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 302 | 0.020 |
Why?
|
| DNA Repair | 1 | 1993 | 376 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2010 | 3974 | 0.020 |
Why?
|
| Physical Examination | 1 | 1992 | 154 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1715 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 514 | 0.020 |
Why?
|
| Superoxides | 1 | 1990 | 76 | 0.020 |
Why?
|
| Differential Threshold | 1 | 1990 | 13 | 0.020 |
Why?
|
| Rejuvenation | 1 | 2010 | 21 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 1990 | 99 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2006 | 2778 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 91 | 0.020 |
Why?
|
| Radiation Injuries | 2 | 1989 | 163 | 0.020 |
Why?
|
| Gangliosides | 2 | 1986 | 10 | 0.020 |
Why?
|
| Amiodarone | 1 | 1989 | 15 | 0.020 |
Why?
|
| Pigmentation Disorders | 1 | 1989 | 13 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1990 | 148 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1992 | 235 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1990 | 1010 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1995 | 841 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2000 | 2418 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2006 | 740 | 0.020 |
Why?
|
| Clinical Trials as Topic | 3 | 1988 | 1179 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1990 | 489 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1989 | 214 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 1994 | 2086 | 0.020 |
Why?
|
| Facial Neoplasms | 1 | 1987 | 26 | 0.020 |
Why?
|
| Necrosis | 1 | 1987 | 210 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 2003 | 311 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1987 | 313 | 0.020 |
Why?
|
| Coproporphyrinogen Oxidase | 1 | 2006 | 1 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2006 | 12 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1989 | 813 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2006 | 44 | 0.020 |
Why?
|
| Trioxsalen | 1 | 1986 | 2 | 0.020 |
Why?
|
| Eyelids | 1 | 1986 | 24 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1986 | 73 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1986 | 75 | 0.010 |
Why?
|
| Thiazoles | 1 | 2006 | 130 | 0.010 |
Why?
|
| Melanocytes | 1 | 1986 | 60 | 0.010 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1986 | 67 | 0.010 |
Why?
|
| Seasons | 1 | 1986 | 246 | 0.010 |
Why?
|
| Amino Acids | 2 | 1997 | 262 | 0.010 |
Why?
|
| 3-Phosphoshikimate 1-Carboxyvinyltransferase | 2 | 1994 | 2 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1988 | 1828 | 0.010 |
Why?
|
| Lymphoma | 1 | 1986 | 271 | 0.010 |
Why?
|
| Chloroplasts | 2 | 1994 | 69 | 0.010 |
Why?
|
| Liver Diseases | 1 | 1986 | 249 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 2578 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1987 | 1094 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2003 | 48 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2002 | 30 | 0.010 |
Why?
|
| Papanicolaou Test | 1 | 2002 | 39 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2002 | 71 | 0.010 |
Why?
|
| Polylysine | 1 | 2001 | 34 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 95 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1753 | 0.010 |
Why?
|
| Skin Temperature | 1 | 1999 | 16 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2001 | 528 | 0.010 |
Why?
|
| Ventilation | 1 | 1999 | 11 | 0.010 |
Why?
|
| Pregnancy | 2 | 1999 | 3240 | 0.010 |
Why?
|
| Sodium Azide | 1 | 1999 | 5 | 0.010 |
Why?
|
| Deuterium Oxide | 1 | 1999 | 10 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1994 | 3040 | 0.010 |
Why?
|
| Catalase | 1 | 1999 | 49 | 0.010 |
Why?
|
| Hematoporphyrins | 1 | 1999 | 1 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1809 | 0.010 |
Why?
|
| Arsenic | 2 | 1996 | 272 | 0.010 |
Why?
|
| Disease Progression | 1 | 2003 | 1562 | 0.010 |
Why?
|
| Lysosomes | 1 | 1999 | 124 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1999 | 433 | 0.010 |
Why?
|
| Spectrometry, Mass, Secondary Ion | 1 | 1997 | 3 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1997 | 41 | 0.010 |
Why?
|
| Oxylipins | 1 | 1997 | 18 | 0.010 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1999 | 127 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1997 | 104 | 0.010 |
Why?
|
| Plant Leaves | 1 | 1997 | 88 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1984 | 1276 | 0.010 |
Why?
|
| Dihematoporphyrin Ether | 1 | 1996 | 4 | 0.010 |
Why?
|
| Metalloporphyrins | 1 | 1996 | 26 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1996 | 18 | 0.010 |
Why?
|
| Administration, Topical | 1 | 1996 | 86 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1997 | 310 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1997 | 436 | 0.010 |
Why?
|
| Tars | 1 | 1996 | 1 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1996 | 10 | 0.010 |
Why?
|
| Cocarcinogenesis | 1 | 1996 | 11 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1999 | 983 | 0.010 |
Why?
|
| Biomarkers | 1 | 2003 | 1930 | 0.010 |
Why?
|
| Retinoids | 1 | 1996 | 18 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1996 | 70 | 0.010 |
Why?
|
| Complement C3 | 1 | 1996 | 58 | 0.010 |
Why?
|
| Dapsone | 1 | 1995 | 11 | 0.010 |
Why?
|
| X-Rays | 1 | 1996 | 139 | 0.010 |
Why?
|
| Rosette Formation | 2 | 1986 | 33 | 0.010 |
Why?
|
| Keratosis | 1 | 1995 | 21 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1996 | 57 | 0.010 |
Why?
|
| Epidermis | 1 | 1996 | 104 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1996 | 165 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1996 | 280 | 0.010 |
Why?
|
| Austria | 1 | 1995 | 16 | 0.010 |
Why?
|
| Switzerland | 1 | 1995 | 19 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1995 | 71 | 0.010 |
Why?
|
| Germany | 1 | 1995 | 80 | 0.010 |
Why?
|
| RNA, Plant | 1 | 1994 | 24 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1996 | 236 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2534 | 0.010 |
Why?
|
| Ferrochelatase | 1 | 1994 | 1 | 0.010 |
Why?
|
| Cyclosporine | 1 | 1995 | 242 | 0.010 |
Why?
|
| Verapamil | 1 | 1994 | 34 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1996 | 281 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1996 | 599 | 0.010 |
Why?
|
| Cytosol | 1 | 1994 | 198 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1994 | 85 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1995 | 193 | 0.010 |
Why?
|
| Allergens | 1 | 1995 | 191 | 0.010 |
Why?
|
| Biological Transport | 1 | 1994 | 412 | 0.010 |
Why?
|
| Opossums | 1 | 1993 | 5 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1993 | 87 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 39 | 0.010 |
Why?
|
| Risk Factors | 2 | 1996 | 5961 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 270 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1994 | 156 | 0.010 |
Why?
|
| Species Specificity | 1 | 1993 | 707 | 0.010 |
Why?
|
| DNA Damage | 1 | 1993 | 392 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 2090 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1993 | 340 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1994 | 382 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 2344 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1989 | 510 | 0.000 |
Why?
|
| Face | 1 | 1989 | 115 | 0.000 |
Why?
|
| Furocoumarins | 1 | 1988 | 2 | 0.000 |
Why?
|
| Chemistry | 1 | 1988 | 54 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1988 | 72 | 0.000 |
Why?
|
| Mesocricetus | 1 | 1988 | 103 | 0.000 |
Why?
|
| Yeasts | 1 | 1988 | 51 | 0.000 |
Why?
|
| Cross-Linking Reagents | 1 | 1988 | 92 | 0.000 |
Why?
|
| Biological Availability | 1 | 1988 | 89 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 1619 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 325 | 0.000 |
Why?
|
| Cricetinae | 1 | 1988 | 542 | 0.000 |
Why?
|
| Genes | 1 | 1988 | 308 | 0.000 |
Why?
|
| Etretinate | 1 | 1986 | 4 | 0.000 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1986 | 42 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1986 | 147 | 0.000 |
Why?
|
| Carbohydrates | 1 | 1986 | 49 | 0.000 |
Why?
|
| Sialic Acids | 1 | 1984 | 18 | 0.000 |
Why?
|
| Neuraminic Acids | 1 | 1984 | 11 | 0.000 |
Why?
|
| Cycloheximide | 1 | 1984 | 58 | 0.000 |
Why?
|
| Trypsin | 1 | 1984 | 95 | 0.000 |
Why?
|
| Lactose | 1 | 1984 | 27 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1996 | 3157 | 0.000 |
Why?
|
| Aging | 1 | 1986 | 766 | 0.000 |
Why?
|
| Mutation | 1 | 1993 | 4374 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1996 | 10287 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1986 | 1316 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1986 | 1471 | 0.000 |
Why?
|